基于AECOPD临床路径构建药学干预路径的实践探讨OA

OBJECTIVE:To observe the role of the pharmaceutical pathway based on the clinical pathway for acute exacerbation of chronic obstructive pulmonary disease(AECOPD)in the treatment of AECOPD patients,and to explore the establishment of the pharmaceutical pathway.METHODS:A total of 74 AECOPD patients admitted to Pizhou Hospital of Traditional Chinese Medicine from April to September 2023 were selected as the study group,and 74 AECOPD patients admitted from April to September 2022 were selected as the control group.Both groups received routine clinical pathway intervention,and the study group received pharmaceutical pathway intervention.The length of hospital stay,total hospitalization cost,hospitalization drug cost,antimicrobial drug use and readmission rate within six months were compared and analyzed between the two groups.RESULTS:The median antimicrobial drug cost,antimicrobial utilization rate and combined antimicrobial use rate in the study group were all lower than those in the control group(P<0.05).There were no statistically significant differences in the length of hospital stay,hospitalization medical cost or hospitalization drug cost between the two groups(P>0.05).The microbial specimen submission rate in the study group was higher than that in the control group(P<0.05).The readmission rate within six months after discharge and the rate of three hospitalizations within six months in the study group were both lower than those in the control group(P<0.05).CONCLUSIONS:The implementation of the pharmaceutical pathway can effectively reduce the antimicrobial treatment cost of patients,promote the rational use of clinical antimicrobial agents,and reduce the readmission rate of patients with acute exacerbation,thereby improving the treatment outcomes of patients with COPD.